Navigation Links
Windhover Announces the "Top Biopharma Projects to Watch"
Date:11/1/2011

cts. Each project has been hand-selected by Windhover's elite selection panel to ensure a high-quality slate of presenters.

"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, VP, Content, for Elsevier Business Intelligence's publications. "Many of the companies we selected in the past have gone on to do big deals, and we expect the same from this years' companies.  90% of the companies haven't presented at major partnering events this year."

Attendees of the Therapeutic Area Partnerships conference benefit from expert analysis of trends and opportunities in licensing and M & A dealmaking, presentations by the industry's foremost thought leaders and decision makers, actionable information on emerging, innovative companies and key licensable projects, strategies to finance and commercialize new products.

To register, contact Pat Cardone at +1 (203) 840-6269 p.cardone@elsevier.com or register on the Therapeutic Area Partnerships website at http://www.tapartnerships.com.

About Windhover Conferences and Elsevier Business Intelligence
Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report, PharmAsia News, The Tan Sheet",Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access, Elsevier Business Intelligence and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit http://www.ElsevierBI.c
'/>"/>

SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
2. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
3. Naurexs Novel Antidepressant GLYX-13 Recognized as One of Windhovers Top 10 Neuroscience Projects to Watch
4. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
5. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
6. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
7. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
8. iBio Announces New US Patent for iBioLaunch™ Technology
9. Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds
10. TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference
11. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... SUNNYVALE, Calif., June 1 Pharmacyclics, Inc. (Nasdaq: ... on Form S-3 with the Securities and Exchange Commission (the ... The rights offering will be made through the distribution of ... stock, par value $0.0001 per share, at a subscription price ...
... ... Generation nonfood Biofuel crops Knowledge Platform ,CJP,s "3rd Global Jatropha Hi-Tech ... all set to provide the most authoritative Knowledge platform for Development ... Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Pharmacyclics Files Registration Statement for Rights Offering 2Pharmacyclics Files Registration Statement for Rights Offering 3Pharmacyclics Files Registration Statement for Rights Offering 4Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 2Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 3Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... Gerton Lab has provided new evidence to clarify the ... required for proper kinetochore function, which plays a critical ... in yeast cells, was published in the most recent ... centromeric nucleosome acts as a guide for the position ...
... have discovered a huge number of new species of ... amid the harsh conditions of the Australian outback. ... new species of invertebrates, which include various insects, small ... led by Professor Andy Austin (University of Adelaide), ...
... a plant in Erie County that has never been recorded ... with the aid of a Mercyhurst College professor on the ... is known to exist in northern U.S. states and in ... until this discovery. WPC scientists found a small population of ...
Cached Biology News:Gerton Lab determines the composition of centromeric chromatin 2Researchers go underground to reveal 850 new species 2Erie County home to plant never before recorded in Pa. 2
Recombinant Rat PTX2/SAP...
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Feline IL-5...
Biology Products: